Get the Stockscreener App
5.145
0.48%
-0.025
After Hours:
5.05
-0.095
-1.85%
Foghorn Therapeutics Inc stock is traded at $5.145, with a volume of 74,883.
It is down -0.48% in the last 24 hours and down -12.50% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$5.17
Open:
$5.05
24h Volume:
74,883
Relative Volume:
0.60
Market Cap:
$290.85M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-2.1987
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+3.31%
1M Performance:
-12.50%
6M Performance:
-16.07%
1Y Performance:
-8.13%
1-Day Range:
$5.03
$5.23
1-Week Range:
$4.475
$5.23
52-Week Range:
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.145 | 292.26M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Can technical indicators confirm Foghorn Therapeutics Inc.’s reversalMarket Sentiment Review & Growth Focused Investment Plans - Newser
Foghorn Therapeutics Inc.’s volatility index tracking explainedQuarterly Profit Summary & Expert Verified Movement Alerts - Newser
Statistical indicators supporting Foghorn Therapeutics Inc.’s strengthQuarterly Trade Summary & Weekly Watchlist for Consistent Profits - Newser
Top Risks to Consider Before Buying Foghorn Therapeutics Inc. StockEarnings Overview Report & Technical Pattern Based Signals - Newser
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - ADVFN Brasil
Foghorn Therapeutics Inc. stock outlook for YEARWeekly Trade Report & AI Powered Buy/Sell Recommendations - Newser
How sentiment analysis helps forecast Foghorn Therapeutics Inc.2025 Market Outlook & Daily Volume Surge Trade Alerts - Newser
Foghorn Therapeutics’ SWOT analysis: innovative cancer therapy stock faces pivotal trials - Investing.com Australia
Using flow based indicators on Foghorn Therapeutics Inc.July 2025 Summary & Community Verified Swing Trade Signals - Newser
Is Foghorn Therapeutics Inc. stock ready for a breakout2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Sentiment analysis tools applied to Foghorn Therapeutics Inc.Treasury Yields & AI Powered Trade Plan Recommendations - Newser
How to escape a deep drawdown in Foghorn Therapeutics Inc.Recession Risk & Community Consensus Picks - Newser
Applying Wyckoff theory to Foghorn Therapeutics Inc. stockTrend Confirmation Scanner with Entry Focus - Newser
How Foghorn Therapeutics Inc. stock performs during market volatility - Newser
Leading vs lagging indicators on Foghorn Therapeutics Inc. performanceQuarterly Market Summary & Stepwise Entry and Exit Trade Signals - Newser
Automated trading signals detected on Foghorn Therapeutics Inc.Smart Entry Signals for Active Traders - Newser
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Understanding Foghorn Therapeutics Inc.’s price movementAI Powered Buy Point Forecast Planner - Newser
How cyclical is Foghorn Therapeutics Inc.’s revenue streamFast Growth Mid Cap Picks - sisain.net
Using data filters to optimize entry into Foghorn Therapeutics Inc.Daily Upside Movement Prediction With Data - Newser
Using portfolio simulators with Foghorn Therapeutics Inc. includedGrowth Watchlist for Long Term Positioning - Newser
Comparing Foghorn Therapeutics Inc. in custom built stock radarsShort-Term Swing Opportunity Summary Sheet - Newser
Is Foghorn Therapeutics Inc. meeting your algorithmic filter criteriaAI Model Forecasting Reversal and Breakout Zones - Newser
Research Analysts Offer Predictions for FHTX Q3 Earnings - Defense World
Will Foghorn Therapeutics Inc. bounce back from current supportAI Driven Swing Trade Forecasting Insight - Newser
Real time alert setup for Foghorn Therapeutics Inc. performanceShort-Term Bounce Forecast for Oversold Stocks - Newser
What high frequency data says about Foghorn Therapeutics Inc.Free Entry Alert With Low Drawdown Strategy - Newser
Can volume confirm reversal in Foghorn Therapeutics Inc.Value Holding Return Summary With Outlook - Newser
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing - Yahoo Finance
Wedbush Research Analysts Boost Earnings Estimates for FHTX - Defense World
How to recover losses in Foghorn Therapeutics Inc. stockSafe Entry Screening with Data Backed Analysis - Newser
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):